Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia

2018 ◽  
Vol 47 (5) ◽  
pp. 550-562 ◽  
Author(s):  
F. Ji ◽  
B. Wei ◽  
Y. H. Yeo ◽  
E. Ogawa ◽  
B. Zou ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Clinical Practice ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Meta Analysis ◽  
Routine Clinical Practice ◽  
Genotype 1 ◽  
Direct Acting Antiviral ◽  
Direct Acting

Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review

2018 ◽  
Vol 13 (5) ◽  
pp. 775-790 ◽  
Author(s):  
Eleonora Tamborini Permunian ◽  
Lorenzo Gervaso ◽  
Victor Gerdes ◽  
Lorenzo Moja ◽  
Luigina Guasti ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Drugs ◽  
Vascular Events ◽  
Direct Acting Antiviral ◽  
Direct Acting

Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients

2020 ◽  
Vol 16 (11) ◽  
pp. 675-686
Author(s):  
Longteng Ma ◽  
Jiluo Liu ◽  
Wei Wang ◽  
Fan Yang ◽  
Ping Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Meta Analysis ◽  
Antiviral Treatment ◽  
Direct Acting Antiviral ◽  
Study Results ◽  
Direct Acting ◽  
Better Than

Aim: It was controversial whether direct-acting antiviral (DAA) is better than interferon-based therapy (IBT) in preventing HCV-related hepatocellular carcinoma (HCC). Therefore, we accomplished this large, stepwise meta-analysis. Materials & methods: The PubMed, Cochrane and ScienceDirect were searched for studies published during January 2009–March 2019. Antiviral type, number of chronic hepatitis C (CHC) patients, number of HCC cases from CHC patients, sustained virological response (SVR) status and important covariate data were extracted from each study. Results & conclusion: It is demonstrated that antiviral treatment reduces the occurrence of HCC in patients with CHC; achieving SVR to antiviral treatment reduces HCC; DAA treatment is not better than IBT in the prophylaxis of HCC; DAA treatment and cirrhosis are independently associated with a higher incidence of HCC than IBT in middle-aged CHC patients who achieve SVR.

Effectiveness of direct‐acting agents for chronic hepatitis C treatment in South America: A systematic review and meta‐analysis

2020 ◽  
Vol 27 (12) ◽  
pp. 1396-1407
Author(s):  
Elio C. Castro Filho ◽  
Juliana Piedade ◽  
Rodolfo Castro ◽  
Paula M. Luz ◽  
Flavia Fernandes ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
South America ◽  
Chronic Hepatitis C ◽  
Meta Analysis ◽  
Hepatitis C Treatment ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document